(TheNewswire)
Thetford Mines, Quebec / TheNewswire / July 3, 2018
– KDA Group Inc. (TSXV: KDA) (“ KDA Group ” or the “
Corporation ”) is proud to announce that it has signed an
agreement for the acquisition of 51% of CanNorth Medic Inc.
“KDA Group is pursuing its mission to develop solutions and services for healthcare providers,
and ultimately, to contribute to the well-being of the general public. This majority shareholder position will allow us to offer
patients innovative cannabis-based medical products” explained Marc Lemieux, President and CEO of KDA Group.
THE POTENTIAL OF MEDICAL CANNABIS
“It has been established that 40% – 60% of
medications on the global market originate from plant extracts, including recent, highly effective chemotherapy agents such as
taxanes. The use of cannabinoids, like all medications, must take place in well-researched and recognized fields such as oncology
and chronic pain, among others. The undeniable potential for cannabinoids to replace other medications that have major side effects
should foster the introduction of medical derivatives of cannabis in clinicians’ treatment arsenal, for the ultimate benefit of
patients. Despite conclusive medical literature, the proven therapeutic benefits of cannabinoids continue to be greatly
underestimated and underused among the general public and in the medical community.”
Dr. Éric Poirier, Surgical Oncologist practising at the Centre Hospitalier Universitaire de
Québec
According to Dr. Poirier, it is unfortunate, even today, that pharmacological derivatives of
cannabis sometimes receive negative press by being misleadingly associated with recreational use and its potential for
abuse. Medical and recreational use of cannabis are two completely different issues.
For example, as reported by D.W. Bowles et al., the medical use of cannabis in oncology represents
less than 3% of all prescriptions in the United States, compared with 8% – 23% in
the Netherlands. 1 The legalization of medical cannabis production in Canada
will also lead to advanced scientific research to identify the most active therapeutic molecules and their best delivery methods.
As with all approved medications, patients and healthcare workers are entitled to expect the best available quality and the
uninterrupted availability of therapeutic products.
KDA GROUP’S CONTRIBUTION
KDA Group’s contribution in this strategic partnership is based on its pharmaceutical expertise
throughout its various divisions.
The agreement is conditional on obtaining all required approvals, including final consent from the
TSX Venture Exchange.
ABOUT KDA GROUP
KDA is a leading generic drug distributor and specialized solution provider in the pharmaceutical
market. Today it is a respected name for quality and expertise among the different stakeholders in the pharmaceutical sector. Its
management team is guided by a vision of continuing to lead the way in Quebec while extending operations across Canada and
internationally. Additional information on the Corporation is available at www.groupekda.ca and on SEDAR at www.sedar.com .
REFERENCE
1- The Intersection between cannabis and cancer in the United States. D.W. Bowles et al, Critical Reviews in
Oncology/Hematology 83 (2012) 1-10
- 30 -
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release from KDA group contains forward-looking statements. Forward-looking statements
are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar
expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek,
should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express
opinions based on current conditions and anticipated developments as well as other factors that Management may deem appropriate
under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions,
particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot
guarantee that these estimates, assumptions, and opinions will prove to be accurate.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in
the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this News
Release.
INFORMATION
Marc Lemieux
Chief Executive Officer
514 622-7370
info@groupekda.ca
Copyright (c) 2018 TheNewswire - All rights reserved.